Almirall S.A. (LBTSF)

Overview

Almirall, S.A. is a leading biopharmaceutical company with a deep commitment to skin health. Founded in 1943 and headquartered in Barcelona, Spain, the company was originally known as Laboratorios Almirall, S.A. before rebranding to Almirall, S.A. in May 2009. Almirall operates on a global scale, providing innovative medicines across Europe, the Middle East, the United States, Asia, and Africa. Its activities encompass the acquisition, manufacturing, storage, and distribution of a diverse portfolio of dermatological medicines. The company is particularly focused on addressing a wide spectrum of skin diseases and disorders thereby significantly improving patient lives worldwide. Almirall has taken a step forward in pioneering research and development through its partnership with Etherna, aiming to create groundbreaking mRNA-based therapies for severe skin conditions, including non-melanoma skin cancer.

Products and Services

Almirall’s product portfolio covers an extensive range of dermatological conditions and diseases, along with medicines in various other therapeutic areas. Below is an overview of their key products and services:

• Skin Diseases: The company’s products target a wide array of skin conditions such as actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis (fungal nail infections), vitiligo, hidradenitis suppurativa, and acne. Almirall also focuses on oncodermatology and the treatment of orphan and rare skin diseases, demonstrating its commitment to providing solutions for both common and less prevalent skin conditions.
• Alimentary Tract and Metabolism: Almirall offers treatments aimed at diseases affecting the alimentary tract and metabolism, addressing essential digestive and metabolic functions.
• Antiinfectives for Systemic Use: The company provides anti-infective medications for systemic use, showcasing its capabilities in combating infectious diseases.
• Cardiovascular, Musculo-skeletal, Respiratory, and Nervous System: This product segment underscores Almirall’s engagement in developing treatments for critical health areas beyond dermatology, including cardiovascular, muscular, respiratory, and neurological disorders.
• Dermatologicals: A core focus for Almirall, this category includes a broad spectrum of topical treatments and products specifically designed for dermatological applications, affirming the company’s stronghold in skin health solutions.
• Genito Urinary System and Sex Hormones: Treatments and medications in this category address conditions relating to the genitourinary system and hormonal imbalances, further diversifying Almirall’s healthcare offerings.
• Immunostimulants: Almirall is engaged in the creation and distribution of immunostimulants, substances that activate or enhance the immune system's response, highlighting its contribution to immunotherapy.
• Systematic Hormonal Preparations: The company’s portfolio includes systematic hormonal preparations, providing essential therapies for disorders related to hormone imbalances.

In addition, Almirall’s strategic alliance with Etherna for the development of new mRNA-based therapies positions the company at the forefront of innovating treatment solutions for severe skin diseases, including non-melanoma skin cancer.